VELscope Vx® Named Best New Diagnostic / Imaging Device by DrBicuspid.com

BURNABY, British Columbia - January 24, 2012 - LED Dental Inc. announced today that its VELscope Vx® oral cancer screening system has just been named the "Best New Diagnostic/Imaging Device" by DrBicuspid.com (http://media3.marketwire.com/r/LED). The VELscope Vx® is exclusively distributed in the U.S. and Canada by Henry Schein, Inc. (NASDAQ:HSIC) (www.henryschein.com).

"In light of the many highly innovative dental imaging devices introduced during the past year, we are thrilled to receive this important award," said Peter Whitehead, founder and CEO of LED Dental and its parent company, LED Medical Diagnostics Inc. (TSX VENTURE:LMD). "The fact that the award is determined by a vote of members who include practicing dental professionals attests to the ease with which the VELscope Vx® is being incorporated into dental practices, and the benefits our technology provides in helping to detect oral cancer."

LED Dental introduced the first generation of VELscope®'s fluorescence visualization technology about five years ago in response to the fact that oral cancer was one of the few types of cancer that had not experienced a significant decline in mortality over the previous several decades. VELscope® technology gives dental practitioners an adjunctive visualization aid that should be used together with, and after, a traditional intra- and extra-oral head and neck exam in hopes of detecting oral lesions that might otherwise have been overlooked.

"Ours was the first adjunctive technology cleared by the FDA and Health Canada to detect cancerous and precancerous lesions that might not be apparent to the naked eye," said Mr. Whitehead. "Our philosophy has always been to build devices that provide added valuable information that helps clinicians make good clinical decisions for their patients, rather trying to tell the clinicians what to do." He emphasized that the results of a VELscope® examination should always be considered within the context of the entire diagnostic process, which includes patient history acquisition, identification of risk factors and appropriate monitoring,and referral of suspect lesions for biopsy as appropriate. He also stressed that surgical biopsy remains the gold standard for diagnosis of oral cancer and other oral disease.

The National Cancer Institute's SEER website (www.seer.cancer.gov) indicates that oral cancer is most often detected in late stages, when the 5-year survival rate is less than 50%. When detected early, however,the 5-year survival rate leaps to approximately 82%. "Because the VELscope Vx® is so sensitive to oral mucosal changes, we can help increase the odds that cancer will be detected in early and even precancerous stages," said Mr. Whitehead. "In fact, VELscope Vx® technology increases the likelihood of detecting all types of oral disease at earlier stages, which is good news for the patient as well as the practice."

Since the launch of the first generation model, over 8,000 VELscope® devices have been purchased by dental practices globally. It is estimated that these devices have been used to conduct over 10 million oral cancer exams during that time, easily making VELscope® the world's number one adjunctive oral cancer screening technology.

The VELscope Vx®, the latest generation of the technology, is the first to offer cordless convenience as well as an optional digital camera and customized bracket that make it easy for dentists to photo-document suspicious lesions that are referred to specialists for surgical biopsy.

DrBicuspid.com is a free, member-driven Web site dedicated to general dentists, specialists, and other dental professionals. DrBicuspid.com's goal is to deliver useful, trustworthy, and relevant news, features, columns, and more that will help dental professionals make their practices better, faster, smoother and more profitable. In addition to the VELscope Vx®, the DrBicuspid.com Dental Excellence Awards 2012 honored winners of four other dental product categories as well as the top dental, hygiene and dental assisting educators, the top dental researcher and the top dental practice management consultant.

About LED Medical Diagnostics Inc.

LED Medical Diagnostics Inc. was founded in 2003 and is headquartered in Burnaby, British Columbia, Canada. Its wholly-owned subsidiary, LED Dental Inc., is the manufacturer of the VELscope Vx® oral cancer screening system. VELscope devices®, the first to apply tissue fluorescence visualization technology to the oral cavity, are used to conduct more screenings for oral cancer and other oral diseases than any adjunctive device in the world. For more information, call +1 (604) 434-4614, or visit www.leddental.com.

For media or investor relations inquiries, please contact:

Mark Komonoski
Investor Relations
LED Medical Diagnostics Inc.
TSX.V: LMD | OTCQX: LEDIF | FSE: LME

Toll-Free: 877.255.8483
Office: 403.255.8483
Mobile: 403.470.8384
E-Mail:
Skype: mkomonoski

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.